ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 2015, the company focuses on developing innovative therapies for cancer treatment, particularly through its expertise in immune-oncology. ALX Oncology is renowned for its lead product candidate, ALX148, which is designed to enhance the immune response against tumours by targeting the CD47 pathway, a unique approach that sets it apart in the competitive landscape. With a strong operational presence in key regions, ALX Oncology has made significant strides in clinical development, achieving notable milestones that underscore its commitment to advancing cancer care. The company’s dedication to pioneering solutions positions it as a leader in the fight against cancer, making substantial contributions to the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does ALX Oncology Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ALX Oncology Holdings Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ALX Oncology Holdings Inc.'s reported carbon emissions
ALX Oncology Holdings Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that ALX Oncology may not have established formal commitments to reduce its carbon footprint or may not yet be participating in recognised climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biotechnology industry, where ALX operates, many companies are increasingly focusing on sustainability and climate commitments. However, without specific emissions data or reduction initiatives, it is unclear how ALX Oncology aligns with these industry trends. As the company progresses, it may consider developing and disclosing its climate strategies to enhance transparency and accountability in its environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ALX Oncology Holdings Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
